4/24/2013

The FDA granted orphan-drug status to the investigational drug XEN402, which is being developed by Teva Pharmaceutical Industries and Xenon Pharmaceuticals to treat pain associated with erythromelalgia. The rare condition leads to attacks of severe burning pain in the hands and feet.

Full Story:
Globes (Israel)

Related Summaries